Proactiveinvestors United Kingdom Sareum Holdings Plc https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Sareum Holdings Plc RSS feed en Sat, 23 Mar 2019 12:15:29 +0000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Sareum Holdings PLC Issue of Options ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190312070004_13998080/ Tue, 12 Mar 2019 07:00:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190312070004_13998080/ <![CDATA[Media files - Sareum's Tim Mitchell looks ahead to critical Phase II data from flagship Chk1 inhibitor ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/12541/sareum-s-tim-mitchell-looks-ahead-to-critical-phase-ii-data-from-flagship-chk1-inhibitor-12541.html Mon, 11 Mar 2019 13:10:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/12541/sareum-s-tim-mitchell-looks-ahead-to-critical-phase-ii-data-from-flagship-chk1-inhibitor-12541.html <![CDATA[News - Sareum boss “very pleased” with progress of flagship Chk1 inhibitor ]]> https://www.proactiveinvestors.co.uk/companies/news/215697/sareum-boss-very-pleased-with-progress-of-flagship-chk1-inhibitor-215697.html Sareum Holdings Plc (LON:SAR) boss Tim Mitchell has said he is “very pleased” with the progress being made by Sierra Oncology – its partner which is taking SRA737 through the clinic.

SRA737, which is a checkpoint kinase 1 (Chk1) inhibitor, was originally discovered by Sareum before Sierra licensed it back in 2016.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

READ: Sareum surges as its flagship Chk1 inhibitor continues to produce encouraging data

Sierra is currently using SRA737 in in two early-stage ovarian cancer studies: one as a monotherapy and another in combination with low-dose gemcitabine – one of the most commonly-prescribed chemotherapies.

Preliminary data from these trials are expected within the next few months.

Last week, Sierra published pre-clinical data which showed that SRA7737 had a “dramatic enhancement” in anti-tumour activity in a lung cancer model when combined with immunotherapy and low dose gemcitabine.

“We are very pleased with the progress that Sierra has made advancing its clinical programmes with SRA737 in recent months and we look forward to seeing preliminary data from these trials, expected in the first half of 2019,” said Mitchell.

“We are also encouraged by the preclinical work that Sierra and co-workers are conducting to support Chk1 inhibition by SRA737 as an attractive mechanism in combination with other leading cancer drug classes, including immuno-oncology drugs and PARP inhibitors.”

TYK2/JAK1 programme also progressing nicely

Away from SRA737, Sareum has invested a lot of time in its TYK2/JAK1 programme.

It has recently selected two molecules – one targeting autoimmune diseases and theother targeting certain types of leukaemia, lymphoma and solid tumours – for preclinical development.

Mitchell added: “With regard to our proprietary programmes, the selection of SDC-1801 and SDC-1802 as preclinical candidates were important achievements and both are now advancing through preclinical programmes with a view to entering clinical trials in 2020.

“We believe that these compounds have excellent qualities and target a mechanism that is gaining credibility and generating growing interest in the pharmaceutical industry. Advancing these two programmes as quickly and as rigorously as possible is the focus of all our current resources.”

£1.5mln cash in the bank

For the six months ended 31 December, Sareum made a loss of £764,000 (H1 17: £722,000).

After raising £850,000 back in November, the company finished the period with £1.54mln of cash in the bank (H1 17: £2.17mln).

Sareum shares fell 6.5% to 0.72p in early deals on Monday.

]]>
Mon, 04 Mar 2019 08:41:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215697/sareum-boss-very-pleased-with-progress-of-flagship-chk1-inhibitor-215697.html
<![CDATA[RNS press release - HALF-YEARLY RESULTS ENDED 31 DECEMBER 2018 ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190304070006_13988213/ Mon, 04 Mar 2019 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190304070006_13988213/ <![CDATA[RNS press release - Sierra Oncology has reported its 2018 Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190228140438_13985760/ Thu, 28 Feb 2019 14:04:38 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190228140438_13985760/ <![CDATA[News - Sareum surges as its flagship Chk1 inhibitor continues to produce encouraging data ]]> https://www.proactiveinvestors.co.uk/companies/news/215509/sareum-surges-as-its-flagship-chk1-inhibitor-continues-to-produce-encouraging-data-215509.html Sareum Holdings PLC (LON:SAR) surged on Thursday morning as its SRA737 checkpoint kinase 1 (Chk1) inhibitor continues to impress.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

READ: Sareum primed for progress

Sierra Oncology Inc (NASDAQ:SRRA), the US firm which has licensed SRA737, has published pre-clinical data showing it had a “dramatic enhancement” in anti-tumour activity when combined with immunotherapy and low dose gemcitabine – one of the most commonly prescribed chemotherapies.

“These new studies reveal a striking immunomodulatory effect of SRA737 + LDG that results in some of the most profound synergistic activity with anti-PD-L1 therapy that we have observed in this model,” said Lauren Byers, associate professor at the University of Texas MD Anderson cancer center.

“We are excited by the potential clinical translatability of these findings and their possible broader impact on immune checkpoint blockade strategies.”

Research house Hybridan added: “This three-way combination is another potential addition to SRA737’s development programme which stands to generate significant further milestones and in due course royalties for Sareum.”

The data is being presented at the American Association of Cancer Research annual meeting in Atlanta, Georgia next month.

In afternoon trading in London, Sareum shares were 12.5% higher 0.68p.

Reporting results today, Sierra CEO Nick Glover commented: "We have enrolled a substantial number of patients into the two ongoing trials for our oral Chk1 inhibitor, SRA737, and remain on track to report clinical data from these studies in the first half of 2019."

In pre-market trading in New York, Sierra Oncology shares were 11.5% higher at $2.0299.

 -- Adds Sierra comment, share price --

]]>
Thu, 28 Feb 2019 09:31:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215509/sareum-surges-as-its-flagship-chk1-inhibitor-continues-to-produce-encouraging-data-215509.html
<![CDATA[RNS press release - New SRA737 preclin data to be presented at AACR ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190228081444_13984977/ Thu, 28 Feb 2019 08:14:44 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190228081444_13984977/ <![CDATA[News - Sareum Holdings primed for progress ]]> https://www.proactiveinvestors.co.uk/companies/news/215154/sareum-holdings-primed-for-progress-215154.html Sareum Holdings PLC's (LON:SAR) most advanced programme was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase II clinical trials conducted by licence partner Sierra Oncology. There are a further two trials planned. The drug developer has two other preclinical discoveries - focused on autoimmune disease and cancer.

SRA737

This is a checkpoint kinase 1 inhibitor, a type of drug that controls a cancer cell's response to DNA damage. Sareum’s NASDAQ-listed partner is currently refining trials of the drug following the emergence of new data. It will focus efforts on a form of ovarian cancer. This “reprioritising and enlarging” of the ongoing Phase I/II studies have meant that the publication of clinical data is now expected to take place in mid-2019. Sierra has suggested read-out will be submitted for presentation at ASCO, America’s largest cancer conference, which takes place at the end of May running into early June.

What else does Sareum have?

Earlier in the pipeline are SDC-1801, for auto-immune diseases, and SDC-1802, for cancer. Preclinical programmes have been mapped out for each discovery with the aim of getting them into the clinic in 2020. Both are members of the Janus Kinase (JAK) family and specifically are TYK2/JAK1 kinases. They work by inhibiting the activity of one or more of the Janus kinase family of enzymes.

What the broker says

Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space.”

]]>
Fri, 22 Feb 2019 15:42:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215154/sareum-holdings-primed-for-progress-215154.html
<![CDATA[RNS press release - Sierra Oncology to present SRA737 at DDR Tx Summit ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190123133833_13944459/ Wed, 23 Jan 2019 13:38:33 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190123133833_13944459/ <![CDATA[News - Sareum Holdings shares soar as Hybridan spotlights read-across from big US pharma takeover deal ]]> https://www.proactiveinvestors.co.uk/companies/news/211924/sareum-holdings-shares-soar-as-hybridan-spotlights-read-across-from-big-us-pharma-takeover-deal-211924.html Sareum Holdings Plc (LON:SAR) saw its shares soar higher on Thursday as analysts at Hybridan spotlighted a read-across from the launch of big pharma takeover deal in the US.

The small-cap broker’s analysts noted that Bristol-Myers Squibb Co. (NYSE:BMY) has agreed to acquire Celgene Corp (NASDAQ:CELG) for US$74bn, with the combined entity to have six expected near-term product launches, representing more than US$15bn in revenue potential.

READ: Sareum Holdings chairman says drug discovery group is making progress

They pointed out that includes Bristol-Myers Squibb’s TYK2 (Tyrosine Kinase 2) protein-coding gene candidate, an inhibitor which is used as a treatment for autoimmune conditions.

The analysts noted that they have previously mused that the inhibitive qualities of Sareum’s two candidates in the same space could mean that, along with other qualities, its assets could emerge as best in class.

They said their review of the clinical evidence so far suggests that Sareum’s JAK1 (Janus kinase) inhibitor – which is one of the same family as TYK2 - could provide some additional efficacy particularly in autoimmune conditions such as Psoriasis.

The analysts concluded that even with today’s share price jump – up 19% to 0.62p in late afternoon trading -- Sareum’s market cap of just £18mln makes the firm “arguably a bargain target for the relatively large group of Biotech and Pharma companies interested in TYK2 and the wider JAK inhibitor space.”

]]>
Thu, 03 Jan 2019 15:49:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211924/sareum-holdings-shares-soar-as-hybridan-spotlights-read-across-from-big-us-pharma-takeover-deal-211924.html
<![CDATA[RNS press release - Results of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181218123540_13908101/ Tue, 18 Dec 2018 12:35:40 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181218123540_13908101/ <![CDATA[News - Sareum Holdings chairman says drug discovery group is making progress ]]> https://www.proactiveinvestors.co.uk/companies/news/211380/sareum-holdings-chairman-says-drug-discovery-group-is-making-progress-211380.html Drug discovery group Sareum Holdings Plc (LON:SAR) will tell investors 2018 has been a year of significant progress.

At the company’s annual meeting, being held in the City of London, chairman Dr Stephen Parker will point to the progress of SRA737, which has been licensed to Sierra Oncology.

Sareum’s NASDAQ-listed partner is currently refining trials of the drug as new data emerged and is prioritising development on high-grade serous ovarian cancer.

Clincial data due by mid-next year

This “reprioritising and enlarging” of the ongoing phase I/II studies have meant that the publication of clinical data is now expected to take place in mid-2019.

Sierra has suggested read-out will be submitted for presentation at ASCO, America’s largest cancer conference, which takes place at the end of May running into early June.

An early-stage trial of SRA737 in patients taking the drug on its own is being carried out at 15 hospitals around the UK and is expected to be concluded in April 2020.

Also ongoing are studies using the treatment in combination with low-dose chemotherapy, while there are plans to use SRA737 in harness with a type of cancer therapy called a PARP inhibitor.

Earlier in the pipeline 

Earlier in the pipeline are SDC-1801, for auto-immune diseases, and SDC-1802, for cancer. Preclinical programmes have been mapped out for each discovery with the aim of getting them into the clinic in 2020.

During the year, Sareum bolstered its governance by appointing two new independent directors to the board - Dr Mike Owen and Clive Birch.

Financially, the group was sitting on around £1.4mln in October and has since gone on to raise a further £850,000.

“The board of directors believes that 2018 has consolidated the progress and increasing maturity reported last year,” chairman Parker will tell investors.

“I would like to thank our shareholders, collaboration partners, suppliers, contractors and other stakeholders for their continued support and look forward to providing further updates on progress in 2019.”

]]>
Tue, 18 Dec 2018 07:52:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211380/sareum-holdings-chairman-says-drug-discovery-group-is-making-progress-211380.html
<![CDATA[RNS press release - AGM Statement ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181218070003_13906997/ Tue, 18 Dec 2018 07:00:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181218070003_13906997/ <![CDATA[RNS press release - Amendment to Preclinical Efficacy Announcement ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181130111754_13887116/ Fri, 30 Nov 2018 11:17:54 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181130111754_13887116/ <![CDATA[News - Sareum’s SRA737 Chk1 inhibitor impresses once again ]]> https://www.proactiveinvestors.co.uk/companies/news/210289/sareums-sra737-chk1-inhibitor-impresses-once-again-210289.html Sareum Holdings Plc (LON:SAR) shares were in demand on Friday morning after Sierra Oncology, the US firm which has licensed Sareum’s SRA737 checkpoint kinase 1 (Chk1) inhibitor candidate, published new data overnight.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

In data presented at an industry conference in Miami on Thursday, SRA737 demonstrated “clear anti-tumour activity” in a preclinical model of small cell lung cancer.

READ: SRA737 could have potential in ovarian cancer

 “We are encouraged by the findings of this study, which was presented at AACR,” said Sareum chief executive Tim Mitchell.

“It showed SRA737 activated the innate immune signalling Stimulator of Interferon Genes (STING) pathway and demonstrated clear anti-tumour activity in an immunocompetent preclinical model of small cell lung cancer.

“These are important findings as SCLC remains a significant unmet need and one where immunotherapies have yielded limited efficacy. These encouraging preclinical results highlight an additional potential opportunity for SRA737 that warrants further evaluation.”

Research house Hybridan added: “This data bodes well for a potential immunotherapy combination study in humans, which if successful further augments the potential scale of future royalties to Sareum, as well as the likelihood of further success milestones.”

Shares rose 5.7% to 0.74p in early deals on Friday.

]]>
Fri, 30 Nov 2018 08:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210289/sareums-sra737-chk1-inhibitor-impresses-once-again-210289.html
<![CDATA[RNS press release - Preclinical Efficacy for Immunotherapy Combination ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181130074505_13886558/ Fri, 30 Nov 2018 07:45:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181130074505_13886558/ <![CDATA[News - Latest data suggests Sareum’s SRA737 Chk1 inhibitor has potential in ovarian cancer ]]> https://www.proactiveinvestors.co.uk/companies/news/209282/latest-data-suggests-sareums-sra737-chk1-inhibitor-has-potential-in-ovarian-cancer-209282.html Sareum Holdings Plc’s (LON:SAR) SRA737 checkpoint kinase 1 (Chk1) inhibitor candidate has potential in certain types of ovarian cancer, according to Sierra Oncology, the US firm which has licensed the compound.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

READ: Preliminary results from SRA737 clinical trials due in H1 2019

Data presented at a cancer convention in Dublin suggested SRA737 showed “promising efficacy” in pre-clinical models of high-grade serous ovarian cancer (HGSOC).

Sareum said the in vivo – i.e. in a living organism – data support the ongoing phase I/II monotherapy clinical trial of the compound, which is enrolling patients with these HGSOC subtypes.

The AIM company also reckons the data supports the idea that SRA737 could be useful when combined with low-dose gemcitabine – one of the most commonly prescribed chemotherapies – or PARP inhibitors, which stop cancer cells repairing themselves.

Sareum boss “encouraged” by data

An early-stage study of the compound with low-dose gemcitabine is already underway, while Sierra is preparing for a trial which will see SRA737 partnered with niraparib, a PARP inhibitor.

“The data presented today continue to provide evidence that SRA737 has potential in ovarian cancer where the tumours exhibit defective cell cycle checkpoint control and replicative stress, and which is identifiable by genetic markers,” said Sareum chief executive Tim Mitchell.

“This represents a significant proportion of HGSOC patients who currently have few treatment options. We are encouraged by the new data, which supports the rationale for Sierra's clinical study with SRA737 as a monotherapy and look forward to updates from the ongoing clinical trials in the first half of 2019.”

Sareum shares rose 4.8% on the back of the announcement to 0.81p.

]]>
Thu, 15 Nov 2018 11:15:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/209282/latest-data-suggests-sareums-sra737-chk1-inhibitor-has-potential-in-ovarian-cancer-209282.html
<![CDATA[RNS press release - Preclinical Data for SRA737 in Ovarian Cancer ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181115102427_13868402/ Thu, 15 Nov 2018 10:24:27 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181115102427_13868402/ <![CDATA[RNS press release - AGM NOTICE ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181114070004_13865884/ Wed, 14 Nov 2018 07:00:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181114070004_13865884/ <![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181113070019_13864242/ Tue, 13 Nov 2018 07:00:19 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181113070019_13864242/ <![CDATA[News - Preliminary results from Sierra Oncology’s clinical trials of Sareum’s SRA737 compound due in H1 2019 ]]> https://www.proactiveinvestors.co.uk/companies/news/208850/preliminary-results-from-sierra-oncologys-clinical-trials-of-sareums-sra737-compound-due-in-h1-2019-208850.html Preliminary results from two early-stage trials featuring Sareum Holdings PLC’s (LON:SAR) SRA737 checkpoint kinase 1 (Chk1) inhibitor cancer candidate are due to be published in the first half of 2019.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

READ: Sareum secures funding for drug programme

US firm Sierra Oncology, which is the licence holder of SRA737, said in its quarterly update it has made “substantial progress” with its two clinical development programmes for the compound.

Sierra is currently undertaking a Phase I/II monotherapy trial – i.e. SRA737 on its own – of the drug in patients with advanced cancer, as well as another Phase I/II study in which SRA737 is being combined with low-dose gemcitabine, one of the most commonly prescribed chemotherapies.

The NASDAQ-listed company said it has made “substantial progress” in recruiting patients with high grade serous ovarian cancer and that it expects to report preliminary efficacy results from these trials in the first half of next year.

Sierra has also been busy preparing for a third trial of SRA737 in combination with niraparib, a PARP inhibitor which stops cancer cells from repairing themselves, in prostate cancer patients, which is expected to begin within the next few months.

]]>
Thu, 08 Nov 2018 13:20:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208850/preliminary-results-from-sierra-oncologys-clinical-trials-of-sareums-sra737-compound-due-in-h1-2019-208850.html
<![CDATA[RNS press release - Sierra Oncology Q3 2018 Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181108122800_13860401/ Thu, 08 Nov 2018 12:28:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181108122800_13860401/ <![CDATA[News - Sareum secures funding for drug programme ]]> https://www.proactiveinvestors.co.uk/companies/news/207911/sareum-secures-funding-for-drug-programme-207911.html Sareum Holdings Plc (LON:SAR) said it had completed a share placing that has raised £850,000.

The proceeds will be used for working capital purposes and to fund the development of its TYK2/JAK1 targets, which are being developed to treat autoimmune disease and cancer.

READ: Sareum selects potential anti-cancer molecule for further development

“We believe we have strong candidates with optimised profiles in these areas and are focused on advancing these into preclinical development towards clinical trials,” said chief executive, Dr Tim Mitchell.

“These new funds, added to our current cash, will enable us to advance these studies and build up the evidence required to facilitate a licensing agreement at an optimal value."

The stock, which closed Thursday at 0.78p, was sold in placing for 0.65p a share.

]]>
Fri, 26 Oct 2018 07:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207911/sareum-secures-funding-for-drug-programme-207911.html
<![CDATA[RNS press release - Completion of Placing ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181026070003_13843283/ Fri, 26 Oct 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181026070003_13843283/ <![CDATA[RNS press release - FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018 ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181001070004_13810059/ Mon, 01 Oct 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181001070004_13810059/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180927130316_13807373/ Thu, 27 Sep 2018 13:03:16 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180927130316_13807373/ <![CDATA[News - Sareum selects potential anti-cancer molecule for further development ]]> https://www.proactiveinvestors.co.uk/companies/news/205729/sareum-selects-potential-anti-cancer-molecule-for-further-development-205729.html Sareum Holdings Plc (LON:SAR) has selected another candidate molecule from its TYK2 inhibitor programme to take through the clinic, this time as a potential therapy for certain cancers.

Earlier this month, the AIM company went with SDC-1801 as a “potentially best-in-class” treatment for autoimmune diseases.

READ: Sareum to further develop ‘potential best-in-class’ autoimmune disease treatment

It has now chosen SDC-1802 which has shown “compelling efficacy” in blocking cancer cell proliferation in leukaemia disease models, while Sareum thinks it could also be used to treat certain kidney, colon, skin and pancreatic cancers.

The compound has the potential for once-daily oral dosing and a good early safety profile, Sareum added.

SDC-1802 works by targeting the TYK2 and JAK1 enzymes, which are known to have roles in promoting cancer growth.

Those enzymes are also involved in the pro-inflammatory responses in autoimmune diseases, which is why Sareum thinks SDC-1802 also has the potential to act as a backup molecule to SDC-1801.

Clinical trials in 2020

“We are very pleased to have formally selected lead candidates from our TYK2 inhibitor programme for both cancer and autoimmune diseases,” said chief executive Tim Mitchell.

“The candidates are distinct small molecules with attractive and highly competitive profiles for development in their respective indications.”

He added: “Both have produced exciting results in preclinical disease models and we believe present valuable opportunities for licensing and/or further development.

“Our focus is now to advance both candidates into clinical studies, which we anticipate beginning in 2020.”

Sareum shares were down 1.3% to 0.76p shortly after the opening bell on Wednesday.

]]>
Wed, 26 Sep 2018 08:20:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205729/sareum-selects-potential-anti-cancer-molecule-for-further-development-205729.html
<![CDATA[RNS press release - TYK2/JAK1 selected for certain cancers ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180926070003_13804513/ Wed, 26 Sep 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180926070003_13804513/ <![CDATA[News - Sareum reports “strong progress” made with in-house and out-licensed drug programmes ]]> https://www.proactiveinvestors.co.uk/companies/news/204614/sareum-reports-strong-progress-made-with-in-house-and-out-licensed-drug-programmes-204614.html Sareum Holdings Plc (LON:SAR) has highlighted the progress made by its in-house and out-licensed drug programmes over the past year.

US firm Sierra Oncology, which is the licence holder of Sareum’s SRA737 checkpoint kinase 1 (Chk1) inhibitor cancer candidate, has made “strong progress” with its two clinical development programmes for the Chk1 inhibitor.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

Two Sierra studies ongoing, one to start soon

A phase I/II monotherapy trial – i.e. SRA737 on its own – of the drug in patients with advanced cancer was expanded by 170 people.

The other phase study, also phase I/II, sees SRA737 combined with low-dose gemcitabine, one of the most commonly prescribed chemotherapies.

This trial was modified to include 80 genetically defined patients in four cancer indications, with a target cohort of ovarian cancer patients replacing the originally proposed bladder cancer patients

The third trial of SRA737 in combination with niraparib, a PARP inhibitor which stops cancer cells from repairing themselves, in prostate cancer patients is expected to begin within the next few months.

Sierra is also in the process of designing a trial for SRA737 and immune checkpoint blockade, with preclinical data providing “evidence of synergy” for this combination.

Good internal progress, too

Sareum has also reported the “good progress” made with advancing its internal TYK2/JAK1 inhibitor programmes.

The company revealed earlier this week that it has selected a candidate molecule to take through the clinic which it thinks could become the new, "potentially best-in-class" treatment for autoimmune diseases.

SDC-1801 had shown “compelling activity” in disease models of psoriasis and rheumatoid arthritis, while AIM-listed Sareum also noted the potential for once-daily oral dosing and a good early safety profile.

The firm is also in the final stages of selecting a TYK2/JAK1 inhibitor targeting cancer indications.

READ: Sareum takes back promising technology

On top of all that, at the start of summer Sareum regained the rights to a pre-clinical technology that it reckons could have the potential to treat acute myeloid leukaemia and other blood-borne cancers.

The Aurora+FLT3 kinase inhibitors were handed back by Hebei Medical University Biomedical Engineering Center (HMUBEC), a Chinese group, which encountered "ongoing issues relating to the intravenous formulation".

The plan is to find another partner for this programme while it focuses time and money on its TYK2 inhibitor candidates.

£1.4mln in the bank

The company ended the fiscal year with just under £1.40mln in the bank, having raised an additional £700,000 last November.

Investors who backed that funding round at 0.7p a share are now sitting on a small profit with the shares up to 0.75p in early deals on Tuesday.

As is common for companies at this formative stage of their development, Sareum was loss-making – to the tune of £1.47mln.

]]>
Tue, 11 Sep 2018 08:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204614/sareum-reports-strong-progress-made-with-in-house-and-out-licensed-drug-programmes-204614.html
<![CDATA[RNS press release - Pre-Close Trading Statement ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180911070009_13785521/ Tue, 11 Sep 2018 07:00:09 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180911070009_13785521/ <![CDATA[News - Sareum to further develop ‘potential best-in-class’ autoimmune disease treatment ]]> https://www.proactiveinvestors.co.uk/companies/news/204493/sareum-to-further-develop-potential-best-in-class-autoimmune-disease-treatment-204493.html Sareum Holdings Plc (LON:SAR) has selected a candidate molecule to take through the clinic which it thinks could become the new, "potentially best-in-class" treatment for autoimmune diseases.

SDC-1801 has shown “compelling activity” in disease models of psoriasis and rheumatoid arthritis, while AIM-listed Sareum also noted the potential for once-daily oral dosing and a good early safety profile.

Closely related molecules have also shown “good activity” in models of inflammatory bowel disease and lupus.

READ: Sareum receives update on progress of cancer drug

“These attributes strongly support the progression of SDC-1801 into preclinical development and, pending satisfactory progress, advancement into human clinical trials, which could begin in 2020,” the statement said.

SDC-1801 works by targeting the TYK2 and JAK1 enzymes which are known to have roles in pro-inflammatory responses in autoimmune diseases and tumour cell proliferation in certain cancers.

A second, ‘back-up’ candidate is expected to be nominated in the near future.

“With SDC-1801, we believe we are entering this space with a strong candidate that exhibits potentially best-in-class features,” said chief executive Tim Mitchell.

“We intend to focus our resources on advancing SDC-1801 through preclinical development and into clinical trials over the next 18 months. At the same time, we will continue our discussions with potential licence partners for this exciting drug candidate.”

]]>
Mon, 10 Sep 2018 07:36:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204493/sareum-to-further-develop-potential-best-in-class-autoimmune-disease-treatment-204493.html
<![CDATA[RNS press release - Selection of TYK2/JAK1 for autoimmune diseases ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180910070004_13783786/ Mon, 10 Sep 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180910070004_13783786/ <![CDATA[News - Sareum Holdings investors receive update on progress of cancer drug ]]> https://www.proactiveinvestors.co.uk/companies/news/202589/sareum-holdings-investors-receive-update-on-progress-of-cancer-drug-202589.html Investors in Sareum Holdings PLC (LON:SAR) received an update on the company’s most advanced drugs candidate via Sierra Oncology (NASDAQ:SRRA), the NASDAQ-listed group with which Sareum has a licensing deal.

SRA737 is a checkpoint kinase-1 (Chk1) inhibitor, one of a new breed of cancer treatments, and is currently Phase I/II trials targeting various strains of the killer disease.

READ: Sareum Holdings pleased as Sierra Oncology advances cancer drug trial

It is being tested as a single therapy, in combination with a low-dose chemotherapy called gemcitabine, and in harness with a PARP inhibitor, which helps cells repair themselves.

Sierra in its update said it further refined its single therapy study to focus on high-grade serous ovarian cancer (HGSOC), “supported by emerging data in the field that provides clinical validation for Chk1 inhibition in this indication”.

Priority to ovarian cancer patients 

“Accordingly, we are prioritising the enrolment of approximately 65 genetically defined HGSOC patients into this trial, while continuing to enrol patients into the trial's other indications, although with lower priority," added Dr Nick Glover, Sierra’s chief executive.

"However, given that this amendment will require time to operationalise, we anticipate preliminary data from our monotherapy trial will be reported in the first half of 2019."

The American company is also planning to give priority to ovarian cancer patients as it recruits for its trial deploying SRA737 alongside the low-dose chemo.

In the Phase II expansion portion of the trial, which is recruiting 80 patients, 20 will be HGSOC sufferers, replacing an originally-proposed cohort of urothelial cancer patients.

Preliminary data from this trial is now expected in the first half of 2019.

Derren Nathan, of small-cap broker Hybridan, said: "We believe that the change in the trial designs to prioritise patients with high grade serous ovarian cancer (HGSOC) optimises the chance of a positive outcome, given the validation of this target evidenced by Lily’s Prexasertib data released earlier this year.

"Pre-clinical data by Sierra is also supportive of this rationale. We therefore believe the trade-off between trial optimisation and slightly extended timeline, is a decision well made."

]]>
Thu, 09 Aug 2018 13:53:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/202589/sareum-holdings-investors-receive-update-on-progress-of-cancer-drug-202589.html
<![CDATA[RNS press release - Sareum notes Sierra Oncology Q2 2018 Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180809131521_13750189/ Thu, 09 Aug 2018 13:15:21 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180809131521_13750189/ <![CDATA[RNS press release - Notification of PCA Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180711093839_13713691/ Wed, 11 Jul 2018 09:38:39 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180711093839_13713691/ <![CDATA[RNS press release - Advisers ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180615070006_13680777/ Fri, 15 Jun 2018 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180615070006_13680777/ <![CDATA[Media files - Sareum Holdings says taking back control of cancer technology is “good news” ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/9419/sareum-holdings-says-taking-back-control-of-cancer-technology-is-good-news-9419.html Thu, 31 May 2018 16:05:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/9419/sareum-holdings-says-taking-back-control-of-cancer-technology-is-good-news-9419.html <![CDATA[News - Sareum Holdings takes back promising cancer technology ]]> https://www.proactiveinvestors.co.uk/companies/news/197987/sareum-holdings-takes-back-promising-cancer-technology-197987.html Sareum Holdings Plc (LON:SAR) said it had regained the rights to a pre-clinical technology that may have the potential to treat acute myeloid leukaemia and other blood-borne cancers.

The Aurora+FLT3 kinase inhibitors were handed back by Hebei Medical University Biomedical Engineering Center (HMUBEC), a Chinese group, which encountered "ongoing issues relating to the intravenous formulation".

This prevented higher doses from being explored to establish maximum-tolerated amount, delaying the completion of toxicity studies, the UK drug developer said.

A number of factors

This was one of a number of factors that prompted the return, added Sareum, which is funding formulation specialists here in the UK to try and resolve the intravenous issues to allow completion of the preclinical studies.

In parallel, the group is exploring whether the drug can be taken by mouth.

The company's chief executive, Dr Tim Mitchell, said the data generated to date from HMUBEC's pre-clinical programme provided "encouraging insights" to the potential of the Aurora+FLT3 inhibitor candidate.

Pleased to regain rights

"We are pleased to regain the worldwide rights to these inhibitors, particularly as recent industry activity suggests a resurgence of interest in Aurora kinase as a target for cancer drugs," he added

Aurora+FLT3 kinase inhibitors target two mechanisms important in the progression of certain cancers – cell division (mitosis) and FLT3 kinase over-activation, which is the most common mutation of acute myeloid leukaemia.

Sareum will now take ownership of all the preclinical data generated by HMUBEC and control of any future preclinical development programme for both intravenous and oral formulations of drug candidates.

"We will provide a further update on our plans with these molecules once we have completed a review of the data and our options," said chief executive Mitchell.

 

]]>
Thu, 31 May 2018 07:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197987/sareum-holdings-takes-back-promising-cancer-technology-197987.html
<![CDATA[RNS press release - Sareum regains rights to Aurora+FLT3 inhibitors ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180531070002_13660633/ Thu, 31 May 2018 07:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180531070002_13660633/ <![CDATA[News - Sareum Holdings pleased as Sierra Oncology advances cancer drug trial ]]> https://www.proactiveinvestors.co.uk/companies/news/196749/sareum-holdings-pleased-as-sierra-oncology-advances-cancer-drug-trial-196749.html Sareum Holdings PLC (LON:SAR) has highlighted the expansion of the patient cohort for a Phase 2 cancer drug trail being carried out by Sierra Oncology.

NASDAQ-listed Sierra is the licence holder for Sareum intellectual property relating to certain potential ‘inhibitor’ drug treatments for cancers.

The American company, in its financial results statement out today, confirmed that the SRA737-02 Phase 1/2 Low Dose Gemcitabine Combination Trial was now expanding its patient cohort.

WATCH: Sareum Holdings PLC heartened by Sierra Oncology progress

"We are very pleased with the progress that Sierra Oncology has made across its clinical trials and future plans with SRA737,” said Dr Tim Mitchell, Sareum chief executive.

“Sierra's clinical development strategy to target genetically defined patients is an approach that is gaining increasing confidence throughout the industry as it selects for patients who might best respond to a particular treatment regimen while potentially shortening the overall development time for novel cancer therapies such as SRA737."

Additionally, it noted that the Phase 2 element of the trial would explore the preliminary efficacy of SRA737 plus low dose gemcitabine – specifically, in prospectively enrolled genetically-defined patients with tumours that “harbour genomic alterations hypothesised to confer sensitivity to Chk1 inhibition via synthetic lethality”.

The cohort expansion is targeting 80 patients across four cancer indications; urothelial carcinoma, small cell lung cancer (SCLC), soft tissue sarcoma, and cervical/anogenital cancer.

Sierra also highlighted, as previously announced, that significant progress was made in the LDG Combo Dose Escalation Phase 1, and the combination regimen was very well-tolerated.

It is anticipated that a further study updated will be provided in the fourth quarter of this year.

]]>
Thu, 10 May 2018 13:33:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/196749/sareum-holdings-pleased-as-sierra-oncology-advances-cancer-drug-trial-196749.html
<![CDATA[RNS press release - SRA737 trial update in Sierra Oncology Q1 Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180510122119_13636592/ Thu, 10 May 2018 12:21:19 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180510122119_13636592/ <![CDATA[RNS press release - Sareum to Present at BioTrinity 2018 in London ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180424070008_13615506/ Tue, 24 Apr 2018 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180424070008_13615506/ <![CDATA[News - Sareum Holdings shares spike ahead of US poster presentations ]]> https://www.proactiveinvestors.co.uk/companies/news/195159/sareum-holdings-shares-spike-ahead-of-us-poster-presentations-195159.html Shares in Sareum Holdings PLC (LON:SAR) rose 9% ahead of poster presentations at a key cancer conference by partner Sierra Oncology.

Sierra is the licence holder for Sareum-developed SRA737. The posters will outline pre-clinical results from its research, including late breaking data. They will be on show at the American Association of Cancer Research annual meeting in Chicago.

WATCH: Sareum Holdings PLC heartened by Sierra Oncology progress

Poster one will reveal that checkpoint kinase-1 inhibitor SRA737 is active in both PARP inhibitor-resistant and CCNE1 high-grade serous ovarian cancers.

Synergies with PARP inhibitor

Poster two will inform delegates the drug “synergises” with PARP inhibitor, niraparib, to kill carcinoma cells via multiple cell death pathways.

PARP inhibitors prevent cancer cells from repairing themselves. PARP stands for poly-ADP ribose polymerase and is found in human cells.

Currently, SRA737 is in Phase I/II clinical trials as a single therapy to treat certain stress-driven cancers.

Sierra is also preparing to test its potential in combination with niraparib to tackle hard-to-treat forms of prostate cancer. 

The shares rose 0.045p to 0.9p.

]]>
Tue, 17 Apr 2018 13:26:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195159/sareum-holdings-shares-spike-ahead-of-us-poster-presentations-195159.html
<![CDATA[RNS press release - AACR 2018 Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180417124547_13607806/ Tue, 17 Apr 2018 12:45:47 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180417124547_13607806/ <![CDATA[Media files - Sareum Holdings PLC heartened by Sierra Oncology progress ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/8917/sareum-holdings-plc-heartened-by-sierra-oncology-progress-8917.html Wed, 21 Mar 2018 12:11:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/8917/sareum-holdings-plc-heartened-by-sierra-oncology-progress-8917.html <![CDATA[News - Sareum Holdings' partner to give poster presentation at Chicago cancer conference ]]> https://www.proactiveinvestors.co.uk/companies/news/193215/sareum-holdings-partner-to-give-poster-presentation-at-chicago-cancer-conference-193215.html Sareum Holdings Plc said a partner developing its lead drug candidate will provide a poster presentation at a top cancer conference taking place next month.

Sierra Oncology will outline late-breaking preclinical results for SRA737 at the American Association of Cancer Research in Chicago.

WATCH: Sareum Holdings PLC heartened by Sierra Oncology progress

The data demonstrate that SRA737 has anti-tumour activity as a single therapy in CCNE1-driven cancer models and in strains of the disease resistant to PARP inhibitors that prevent cancer cells repairing themselves.

Sierra says the preclinical results warrant further investigation in human clinical studies.

The poster session is scheduled for April 17 from 1pm to 5pm.

]]>
Thu, 15 Mar 2018 08:08:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/193215/sareum-holdings-partner-to-give-poster-presentation-at-chicago-cancer-conference-193215.html
<![CDATA[RNS press release - Late-breaker abstract for SRA737 accepted for AACR ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180315070006_13567532/ Thu, 15 Mar 2018 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180315070006_13567532/ <![CDATA[News - Sareum update reveals extent of progress made by co's licence partner ]]> https://www.proactiveinvestors.co.uk/companies/news/193047/sareum-update-reveals-extent-of-progress-made-by-co-s-licence-partner-193047.html Interim results from Sareum Holdings PLC (LON:SAR) charted a period of significant progress for the cancer drug developer and its licence partner Sierra Oncology.

Sareum said Sierra had made “strong progress” with the two clinical studies of its Checkpoint kinase 1, or Chk1 inhibitor, SRA737.

This has led to a significant expansion of the development programme going into 2018.

Last month Sierra said the Phase I portion of the Phase I/II clinical trial of SRA737 as a single cancer therapy was in the final stages.

Phase II group expanded

Encouragingly, Phase II has been expanded to include more patients across six cancer indications and at a larger number of clinical sites.

In parallel, Sierra is running a Phase I/II trial using SRA737 in combination with low-dose Gemcitabine, one of the most commonly prescribed chemotherapies.

Phase II of this trial is expected to get underway in the second-quarter, with the enrolment of 80 genetically selected patients across four indications.

Sierra plans to start an early-stage clinical study of SRA737 in combination with a PARP inhibitor in the final quarter of the year. PARP inhibitors prevent cancer cells repairing themselves.

Chief executive, Dr Tim Mitchell, said he had been “encouraged” by Sierra’s progress and by the potential of SRA737 to treat multiple cancers.

“We look forward to initial results from the innovative clinical trials expected in the fourth quarter of 2018 and further programme updates during the year,” he added.

Separately, Sareum said its TYK2 inhibitor autoimmune disease and cancer research programmes advanced with “distinct small molecules” moving into candidate selection for pre-clinical development. CEO Mitchell said he was “pleased” with the progress in this regard.

Rude financial health

The company ended last year with just under £2.2mln in the bank, having raised an additional £700,000 in November.

Investors who backed that funding round at 0.7p a share are now sitting on a decent profit with the shares closing Monday at 0.9p.

As is common for companies at this formative stage of their development, Sareum was loss-making – to the tune of £722,000.

READ: Clinical development programme expands  ]]>
Tue, 13 Mar 2018 07:43:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/193047/sareum-update-reveals-extent-of-progress-made-by-co-s-licence-partner-193047.html
<![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180313070002_13564100/ Tue, 13 Mar 2018 07:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180313070002_13564100/ <![CDATA[News - Sareum Holdings: Sierra has ‘significantly expanded’ clinical development programme for its cancer drug ]]> https://www.proactiveinvestors.co.uk/companies/news/192288/sareum-holdings-sierra-has-significantly-expanded-clinical-development-programme-for-its-cancer-drug-192288.html Drug development company Sareum Holdings Plc (LON:SAR) reported that Sierra Oncology Inc (NASDAQ:SRRA), the licence holder advancing clinical cancer candidate SRA737, announced that it has significantly expanded’ its clinical development programme.

Sierra Holdings has announced ‘noteworthy progresses’ in the Dose Escalation Phase 1 portions for both of its ongoing Phase I/II clinical trials involving Chk1 inhibitor, SRA737.

Sareum Holdings: Pre-clinical data for new cancer combination to be presented to US peers

Phase 2 portions of both trials (efficacy) will be expanded to approximately 200 patients across ten cancer indications.

Sierra has also announced it is planning to initiate a Phase 1b/2 clinical trial in the fourth quarter of 2018 that will evaluate SRA737 in combination with ZEJULA (niraparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Sierra Oncology holds exclusive and worldwide right for the Chk1 inhibitor, SRA737, which it licensed from the CRT Pioneer Fund, a partner of  Sareum, in September 2016.

]]>
Tue, 27 Feb 2018 14:59:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/192288/sareum-holdings-sierra-has-significantly-expanded-clinical-development-programme-for-its-cancer-drug-192288.html